Clinical Trials Logo

Clinical Trial Summary

This phase II trial studies efficacy of extracorporeal photopheresis and low dose aldesleukin (interleukin-2) in treating patients with chronic graft-versus-host disease (cGVHD) that does not respond to upfront treatment with steroids. In graft-vs-host disease, patients have a small quantity of a white blood cell called T regulatory cells or T-reg cells that helps to control the immune system. Extracorporeal photopheresis is a procedure where patient's blood is removed and treated with ultraviolet light and drugs that become active when exposed to light. The treated blood is then returned to the patient and may be effective in increasing T-reg cells in patients with cGVHD. Aldesleukin increases the activity and growth of white blood cells, and it has shown to enhance T-reg cells in patients with cGVHD and may be effective improving GVHD symptoms.

Clinical Trial Description

PRIMARY OBJECTIVES: I. To evaluate the anti-cGVHD activity of extracorporeal photopheresis (ECP) when combined with low dose IL-2 (interleukin 2) (aldesleukin), in patients with steroid refractory cGVHD, as assessed by overall cGVHD response rate (complete response [CR]+partial response [PR]+stable disease [SD]). SECONDARY OBJECTIVES: I. Characterize and evaluate toxicities, including type, frequency, severity, attribution, time course and duration. II. Estimate overall and failure-free survival, non-relapse mortality (NRM) and relapse, through 1 year after initiation of treatment. III. Characterize chronic GVHD Symptom Scale scores -self-report (with assistance from register nurses [RNs] and medical doctors [MDs]). IV. Assess the immunologic effects of low-dose daily subcutaneous (SC) IL-2 + ECP. V. Correlate clinical endpoints of response with ECP performance parameters. OUTLINE: Patients receive aldesleukin subcutaneously (SC) daily for 12 weeks. Patients also undergo ECP twice weekly on weeks 1-4 and then receive 2 ECP treatments every 2 weeks on weeks 5-12. Patients responding to upfront therapy with aldesleukin and ECP have the option to continue combination therapy per the discretion of the treating physician until clinical benefit is maintained or toxicities develop. After completion of study treatment, patients are followed up periodically. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT03007238
Study type Interventional
Source City of Hope Medical Center
Status Active, not recruiting
Phase Phase 2
Start date November 17, 2016
Completion date December 17, 2021

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT01804686 - A Long-term Extension Study of PCI-32765 (Ibrutinib) Phase 3
Terminated NCT02337517 - Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease Phase 2
Terminated NCT02461134 - Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD Phase 2
Recruiting NCT03839069 - Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis N/A
Active, not recruiting NCT00637689 - Improving Outcomes Assessment in Chronic GVHD
Active, not recruiting NCT01954979 - A Phase I Study of Abatacept in the Treatment of Patients With Steroid Refractory Chronic Graft Versus Host Disease (cGVHD) Phase 1
Active, not recruiting NCT01937468 - Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease Phase 1
Completed NCT01810718 - Phase I/II for Safety and Efficacy of Nilotinib in a Population Steroid-refractory/or Steroid-dependent cGVHD Phase 1
Completed NCT01380535 - Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD) Early Phase 1
Terminated NCT01964625 - Positron Emission Tomography - Computed Tomography (PET-CT) Scanning in Chronic Graft Versus Host Disease (cGvHD) N/A
Recruiting NCT03790332 - Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD) Phase 1/Phase 2
Active, not recruiting NCT01680965 - Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease Phase 1/Phase 2
Completed NCT02491359 - Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease Phase 2
Terminated NCT02701634 - Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD) Phase 2
Recruiting NCT04212416 - Leflunomide in Treating Patients With Steroid Dependent Chronic Graft Versus Host Disease Phase 1
Completed NCT02959944 - Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD) Phase 3
Completed NCT03483675 - Discontinuation or Continuation of Immunosuppressive Therapy in Participants With Chronic Graft Versus Host Disease Phase 2
Recruiting NCT04431479 - Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study
Recruiting NCT04944043 - A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease Phase 1/Phase 2
Completed NCT00656058 - Montelukast to Treat Bronchiolitis Obliterans Phase 2